{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T02:42:13Z","timestamp":1780368133811,"version":"3.54.1"},"reference-count":34,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hum. Psychopharmacol Clin Exp"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1002\/hup.2542","type":"journal-article","created":{"date-parts":[[2016,6,14]],"date-time":"2016-06-14T03:17:31Z","timestamp":1465874251000},"page":"325-331","source":"Crossref","is-referenced-by-count":18,"title":["Haloperidol versus second-generation antipsychotics in the long-term treatment of schizophrenia"],"prefix":"10.1002","volume":"31","author":[{"given":"Massimiliano","family":"Buoli","sequence":"first","affiliation":[{"name":"Department of Psychiatry; University of Milan; Milan Italy"},{"name":"Department of Psychiatry, Brain Center Rudolf Magnus; University Medical Center Utrecht; Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9 S.","family":"Kahn","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Brain Center Rudolf Magnus; University Medical Center Utrecht; Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Serati","sequence":"additional","affiliation":[{"name":"Department of Psychiatry; University of Milan; Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Carlo","family":"Altamura","sequence":"additional","affiliation":[{"name":"Department of Psychiatry; University of Milan; Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiepke","family":"Cahn","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Brain Center Rudolf Magnus; University Medical Center Utrecht; Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,6,13]]},"reference":[{"key":"10.1002\/hup.2542-BIB0001|hup2542-cit-0001","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/JCP.0b013e31822c989a","article-title":"Haloperidol versus second-generation antipsychotics in the long-term treatment of schizophrenia: a 4-year follow-up naturalistic study","volume":"31","author":"Altamura","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"10.1002\/hup.2542-BIB0002|hup2542-cit-0002","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1177\/0004867413492572","article-title":"Should the term \u2018antipsychotic\u2019 be changed to \u2018multidimensional stabiliser\u2019 in bipolar disorder? Towards a new denomination for \u2018atypical antipsychotics\u2019","volume":"47","author":"Altamura","year":"2013","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1002\/hup.2542-BIB0003|hup2542-cit-0003","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3109\/08039488.2014.990919","article-title":"Is duration of illness really influencing outcome in major psychoses?","volume":"69","author":"Altamura","year":"2015","journal-title":"Nord J Psychiatry"},{"key":"10.1002\/hup.2542-BIB0004|hup2542-cit-0004","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","article-title":"Remission in schizophrenia: proposed criteria and rationale for consensus","volume":"162","author":"Andreasen","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1002\/hup.2542-BIB0005|hup2542-cit-0005","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.biopsych.2009.08.040","article-title":"Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs","volume":"67","author":"Andreasen","year":"2010","journal-title":"Biol Psychiatry"},{"key":"10.1002\/hup.2542-BIB0006|hup2542-cit-0006","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1477-7525-6-105","article-title":"Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation","volume":"6","author":"Briggs","year":"2008","journal-title":"Health Qual Life Outcomes"},{"key":"10.1002\/hup.2542-BIB0007|hup2542-cit-0007","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.schres.2015.10.013","article-title":"Gender differences in the treatment of first-episode schizophrenia: results from the European First Episode Schizophrenia Trial","volume":"169","author":"Ceskova","year":"2015","journal-title":"Schizophr Res"},{"key":"10.1002\/hup.2542-BIB0008|hup2542-cit-0008","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1177\/0269881110388332","article-title":"Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison","volume":"25","author":"Crespo-Facorro","year":"2011","journal-title":"J Psychopharmacol"},{"key":"10.1002\/hup.2542-BIB0009|hup2542-cit-0009","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00213-011-2392-3","article-title":"Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis","volume":"219","author":"Crespo-Facorro","year":"2012","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1002\/hup.2542-BIB0010|hup2542-cit-0010","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/YCO.0000000000000150","article-title":"The problem of substance abuse in people with schizophrenia","volume":"28","author":"DeLisi","year":"2015","journal-title":"Curr Opin Psychiatry"},{"key":"10.1002\/hup.2542-BIB0033|hup2542-cit-0033","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.4088\/JCP.v69n1208","article-title":"Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study","volume":"69","author":"Dossenbach","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"10.1002\/hup.2542-BIB0011|hup2542-cit-0011","volume-title":"Structured Clinical Interview for DSM-IV Axis I (SCID-I), Clinician Version","author":"First","year":"1997"},{"key":"10.1002\/hup.2542-BIB0012|hup2542-cit-0012","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/phar.1313","article-title":"Adverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review","volume":"33","author":"Gentile","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1002\/hup.2542-BIB0013|hup2542-cit-0013","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.4088\/JCP.11r06927","article-title":"Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach","volume":"72","author":"Glick","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"10.1002\/hup.2542-BIB0014|hup2542-cit-0014","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1093\/schbul\/sbs118","article-title":"Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects","volume":"39","author":"Haijma","year":"2013","journal-title":"Schizophr Bull"},{"key":"10.1002\/hup.2542-BIB0034|hup2542-cit-0034","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4088\/JCP.08m04310","article-title":"The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies","volume":"70","author":"Janicak","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"10.1002\/hup.2542-BIB0015|hup2542-cit-0015","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"key":"10.1002\/hup.2542-BIB0016|hup2542-cit-0016","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJM199601043340109","article-title":"Schizophrenia","volume":"334","author":"Kane","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1002\/hup.2542-BIB0017|hup2542-cit-0017","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/hup.2332","article-title":"Attitude towards second-generation antipsychotics among patients with schizophrenia and their relatives","volume":"28","author":"Karthik","year":"2013","journal-title":"Hum Psychopharmacol"},{"key":"10.1002\/hup.2542-BIB0018|hup2542-cit-0018","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1016\/j.clinthera.2009.12.017","article-title":"The association between class of antipsychotic and rates of hospitalization: results of a retrospective analysis of data from the 2005 Medicare current beneficiary survey","volume":"31","author":"Kennedy","year":"2009","journal-title":"Clin Ther"},{"key":"10.1002\/hup.2542-BIB0019|hup2542-cit-0019","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0924-977X(97)00041-2","article-title":"Drug treatment of the negative symptoms of schizophrenia","volume":"8","author":"King","year":"1998","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1002\/hup.2542-BIB0020|hup2542-cit-0020","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/mp.2011.143","article-title":"Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics","volume":"18","author":"Kishimoto","year":"2013","journal-title":"Mol Psychiatry"},{"key":"10.1002\/hup.2542-BIB0021|hup2542-cit-0021","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophr Res"},{"key":"10.1002\/hup.2542-BIB0022|hup2542-cit-0022","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(12)60239-6","article-title":"Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis","volume":"379","author":"Leucht","year":"2012","journal-title":"Lancet"},{"key":"10.1002\/hup.2542-BIB0023|hup2542-cit-0023","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1192\/bjp.bp.107.037218","article-title":"CATIE and CUtLASS: can we handle the truth?","volume":"192","author":"Lewis","year":"2008","journal-title":"Br J Psychiatry"},{"key":"10.1002\/hup.2542-BIB0024|hup2542-cit-0024","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1001\/jama.2014.4310","article-title":"Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial","volume":"311","author":"McEvoy","year":"2014","journal-title":"JAMA"},{"key":"10.1002\/hup.2542-BIB0025|hup2542-cit-0025","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/epirev\/mxn001","article-title":"Schizophrenia: a concise overview of incidence, prevalence, and mortality","volume":"30","author":"McGrath","year":"2008","journal-title":"Epidemiol Rev"},{"key":"10.1002\/hup.2542-BIB0026|hup2542-cit-0026","first-page":"119","article-title":"Neuroimaging and plasticity in schizophrenia","volume":"32","author":"Meyer-Lindenberg","year":"2014","journal-title":"Restor Neurol Neurosci"},{"key":"10.1002\/hup.2542-BIB0027|hup2542-cit-0027","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/schbul\/sbu128","article-title":"Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study","volume":"41","author":"Nielsen","year":"2015","journal-title":"Schizophr Bull"},{"key":"10.1002\/hup.2542-BIB0028|hup2542-cit-0028","first-page":"916198","article-title":"Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review","volume":"2012","author":"Ochoa","year":"2012","journal-title":"Schizophr Res Treat"},{"key":"10.1002\/hup.2542-BIB0029|hup2542-cit-0029","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1192\/bjp.bp.113.127753","article-title":"Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis","volume":"205","author":"Penttil\u00e4","year":"2014","journal-title":"Br J Psychiatry"},{"key":"10.1002\/hup.2542-BIB0030|hup2542-cit-0030","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.eurpsy.2008.11.002","article-title":"Belgian Schizophrenia Outcome Survey-results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol","volume":"24","author":"Peuskens","year":"2009","journal-title":"Eur Psychiatry"},{"key":"10.1002\/hup.2542-BIB0031|hup2542-cit-0031","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/schbul\/sbt096","article-title":"Intermittent drug techniques for schizophrenia","volume":"39","author":"Sampson","year":"2013","journal-title":"Schizophr Bull"},{"key":"10.1002\/hup.2542-BIB0032|hup2542-cit-0032","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.euroneuro.2012.05.001","article-title":"Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis","volume":"23","author":"Soares-Weiser","year":"2013","journal-title":"Eur Neuropsychopharmacol"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.2542","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/hup.2542","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,8,6]],"date-time":"2018-08-06T17:05:49Z","timestamp":1533575149000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/hup.2542"}},"subtitle":["Long-Term Treatment of Schizophrenia"],"short-title":[],"issued":{"date-parts":[[2016,6,13]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,7]]}},"URL":"https:\/\/doi.org\/10.1002\/hup.2542","archive":["Portico"],"relation":{},"ISSN":["0885-6222"],"issn-type":[{"value":"0885-6222","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6,13]]}}}